Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Pharmacogenetics

Volumn 14, Issue 8, 2004, Pages 501-515

  Girard, Hugo ^a   Court, Michael H ^b   Bernard, Olivier ^a   Fortier, Louis Charles ^a   Villeneuve, Lyne ^a   Hao, Qin ^b   Greenblatt, David J ^b   Von Moltke, Lisa L ^b   Perussed, Louis ^a   Guillemette, Chantal ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Drug metabolism; Glucuronosyltransferase; Mass spectrum analysis; Mycophenolic acid; Pharmacogenetics; Polymorphism

Indexed keywords

DNA BASE; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID; PROPOFOL;

ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DETOXIFICATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE INSERTION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC SCREENING; GENETIC VARIABILITY; GLUCURONIDATION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS);

INSERTION SEQUENCES;

EID: 4143072423     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114754.08559.27     Document Type: Article

References (60)

1. Dutton GJ. Glucuronidation of drugs and other compounds. Boca Raton, FL: CRC Press; 1980.
2. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bèlanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7:255-269.
3. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616.
4. UDP Glucuronosyltransferase home page, http://som.flinders.edu.au/FUSA/ ClinPharm/UGT.
5. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11:357-368.
6. Strassburg CP, Nguyen N, Manns MP, Tukey RH. UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 1999; 116:149-160.
7. Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B, Wynalda MA, et al. Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica 2003; 33:1073-1083.
8. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.
9. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260:199-202.
10. Ethell BT, Riedel J, Englert H, Jantz H, Oekonomopulos R, Burchell B, et al. Glucuronidation of HMR1098 in human microsomes: evidence for the involvement of UGT1A1 in the formation of S-glucuronides. Drug Metab Dispos 2003; 31:1027-1034.
11. Wynalda MA, Wynalda KM, Amore BM, Fagerness PE, Wienkers LC, Ethell BT, et al. Characterization of bropirimine O-glucuronidation in human liver microsomes. Xenobiotica 2003; 33:999-1011.
12. Watanabe Y, Nakajima M, Yokoi T. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 2002; 30:1462-1469.
13. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, et al. HNF4 alpha governs the expression of UGT1A9 in human liver. Submitted.
14. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993; 21:50-55.
15. Kuehl GE, Murphy SE, Yueh MF, Nguyen N, Famourzadeh M, Strassburg CP, et al. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2003; 31:1361-1368.
16. Yueh MF, Nguyen N, Famourzadeh M, Strassburg CP, Oda Y, Guengerich FP, et al. The contribution of UDP-glucuronosyltransferase 1A9 on CYP1A2-mediated genotoxicity by aromatic and heterocyclic amines. Carcinogenesis 2001; 22:943-950.
17. Ciotti M, Lakshmi VM, Basu N, Davis BB, Owens IS, Zenser TV, et al. Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis 1999; 20:1963-1969.
18. Nowell SA, Massengill JS, Williams S, Radominska-Pandya A, Tephly TR, Cheng Z, et al. Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5- b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Carcinogenesis 1999; 20:1107-1114.
19. Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997; 57:2979-2985.
20. Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 2002; 19:588-594.
21. Congiu M, Mashford ML, Slavin JL, Esmond PV. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 2002; 30:129-134.
22. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP- glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299:998-1006.
23. Nakajima M, Sakata N, Ohashi N, Kume T, Yokoi T. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug Metab Dispos 2002; 30:1250-1256.
24. Nakajima M, Tanaka E, Kwon JT, Yokoi T. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos 2002; 30:1484-1490.
25. Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. J Clin Pharmacol 2003; 43:1124-1135.
26. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, et al. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 2001; 29:407-414.
27. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003; 306:688-693.
28. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307:117-128.
29. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30:1257-1265.
30. Lanouette CM, Giacobino JP, Perusse L, Lacaille M, Yvon C, Chagnon M, et al. Association between uncoupling protein 3 gene and obesity-related phenotypes in the Quebec Family Study. Mol Med 2001; 7:433-441.
31. Simonen RL, Perusse L, Rankinen T, Rice T, Rao DC, Bouchard C. Familial aggregation of physical activity levels in the Quebec Family Study. Med Sci Sports Exerc 2002; 34:1137-1142.
32. Ukkola O, Perusse L, Chagnon YC, Despres JP, Bouchard C. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 2001; 25:1332-1339.
33. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14:329-332.
34. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Court MH. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 2003; 31:133-139.
35. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, et al. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003; 31:1125-1133.
36. Bernard O, Guillemette C. In vitro glucuronidation of mycophenolic acid by human UGTs and the impact their polymorphic isoenzymes. Drug Metab Dispos 2004; 32:775-778.
37. Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. Ver 2.000. Genetics and Biometry Lab, Dept. of Anthropology, University of Geneva; 2000.
38. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
39. Quandt K, Frech K, Karas H, Wingender E, Werner T. Matind and Matlnspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23:4878-4884.
40. Bernard O, Guillemette C. In vitro glucuronidation of mycophenolic acid by human UGTs and the impact of known polymorphisms of UGT1A8, UGT1A9 and UGT2B7. in 12th North American Meeting of the International Society for the Study of Xenobiotics (ISSX), Providence (RI, USA), 12-16 October (#106), 2003.
41. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50:259-265.
42. Guillemette C, Villeneuve L. Substrate-dependant impact of a novel UGT1A9 polymorphism. In 8th European ISSX-meeting, Dijon, France, April 27-May 1, 2003.
43. Bosma P, Chowdhury J, Jansen P. Genetic inheritance of Gilbert's syndrome. Lancet 1995; 346:314-315.
44. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-581.
45. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170-8174.
46. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60:950-956.
47. Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the UDP-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004; 75:223-233.
48. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47.
49. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
50. Duguay Y, McGrath M, Lépine J, Gagné J, Hankinson S, Colditz G, et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 2004; 64:1202-1207.
51. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator- activated receptor alpha and gamma target gene. J Biol Chem 2003; 278:13975-13983.
52. Gregory PA, Gardner-Stephen DA, Lewinsky RH, Duncliffe KN, Mackenzie Pl. Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an interior-like region. J Biol Chem 2003; 278:36107-36114.
53. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP- glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001; 121:1136-1144.
54. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001; 93:1411-1418.
55. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001; 10:711-714.
56. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10:629-644.
57. Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 2002; 50:851-856.
58. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, Marberger M, et al. A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:497-498.
59. MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7:777-782.
60. Gestl SA, Green MD, Shearer DA, Frauenhoffer E, Tephly TR, Weisz J. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 2002; 160:1467-1479.